COPENHAGEN - Bavarian Nordic A/S (OMX:CSE:BAVA) shares fell 10% after the Danish vaccine maker reported preliminary 2024 results and provided 2025 guidance that failed to impress investors. The ...
Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...
The consolidated, audited financial results for 2024 will become available on March 5, 2025, in connection with the publication of the Company's Annual Report for 2024. 2025 financial guidance For ...
First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya ...
If authorised, Vimkunya would be the first vaccine in the EU to protect adolescents aged 12 to 17 against Chikungunya.
This table compares Bavarian Nordic A/S and Vir Biotechnology’s net margins, return on equity and return on assets. Bavarian Nordic A/S develops, manufactures, and commercializes life-saving ...
Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 9, ...
COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA ...
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to ...